Xiong Yu, Bensoussan Danièle, Decot Véronique
Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France; Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Zhongnan Hospital of Wuhan University, Wuhan, China.
Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France; Nancy Université, UL-UMR CNRS 7365, Faculté de Médecine, Vandoeuvre-lés-Nancy, Nancy, France.
Transfus Med Rev. 2015 Oct;29(4):259-67. doi: 10.1016/j.tmrv.2015.07.001. Epub 2015 Jul 10.
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with chemotherapy-resistant hematologic malignancies that are usually fatal in absence of treatment. Hematopoietic stem cell transplantation is associated with significant early and late morbidity and mortality. Graft-versus-host disease, infections, and relapse are the most important causes of mortality after HSCT. Until now, these complications have been managed mainly with pharmacological drugs, but in some situations, this approach clearly shows its limit. As such, there is a significant need for novel therapies for the treatment of complications after allogeneic HSCT. In this review, the currently available adoptive immunotherapies offering an alternative in case of treatment failure of HSCT complications will be described. The results of the main clinical trials based on immune cell infusion will be discussed and the strategies aiming at maximizing cytotoxic T-lymphocyte, regulatory T-cell, natural killer cell, cytokine-induced killer cell, and γδ T-cell efficacies in the context of immunotherapy approaches after allogeneic HSCT in patients with hematologic malignancies will be gathered.
造血干细胞移植（HSCT）是化疗耐药血液系统恶性肿瘤患者的唯一治愈性疗法，这类疾病若不治疗通常会致命。造血干细胞移植与显著的早期和晚期发病率及死亡率相关。移植物抗宿主病、感染和复发是HSCT后最重要的死亡原因。到目前为止，这些并发症主要通过药物治疗，但在某些情况下，这种方法显然显示出其局限性。因此，迫切需要新的疗法来治疗异基因HSCT后的并发症。在这篇综述中，将描述目前可用的过继性免疫疗法，这些疗法在HSCT并发症治疗失败的情况下提供了一种替代方案。将讨论基于免疫细胞输注的主要临床试验结果，并收集旨在使血液系统恶性肿瘤患者异基因HSCT后免疫治疗中细胞毒性T淋巴细胞、调节性T细胞、自然杀伤细胞、细胞因子诱导的杀伤细胞和γδT细胞疗效最大化的策略。
